This website is intended for healthcare professionals. If you are a member of the public, please click here

 

<font size="4.5">When to use FERACCRU<sup>®</sup></font>

When to use FERACCRU®

Potential place for FERACCRU® in the treatment pathway

 

 

Diagram does not represent clinical guidelines for the management of IDA

FERACCRU® should not be used in patients with an inflammatory bowel disease (IBD) flare or in IBD patients with haemoglobin (Hb) <9.5 g/dl1

World Health Organization (WHO) definitions for mild, moderate and severe anaemia can be found here2

 

Please refer to the prescribing information and GB SPC or NI SPC before prescribing.

References

  1. FERACCRU® Summary of Product Characteristics. Available for the UK from: https://www.medicines.org.uk/emc. Available for Northern Ireland from: https://www.emcmedicines.com/en-GB/northernireland/
  2. World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. VMNIS. 2011. Available at: http://www.who.int/vmnis/indicators/haemoglobin.pdf
External Link

You are now leaving a Norgine website and entering a third-party website.
Norgine is not responsible for the content of external websites.

Please confirm you wish to follow this link.

Continue Cancel